Dudediligence.

Aytu BioPharma, Inc

AYTUNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$16.6MSep ’24$16.2MDec ’24$18.5MMar ’25$15.1MJun ’25$13.9MSep ’25$15.2MDec ’25$12.4MMar ’26$16.1MJun ’26
Net income, by quarter
$1.5MSep ’24$788,000Dec ’24$4.0MMar ’25−$19.8MJun ’25$2.0MSep ’25−$10.6MDec ’25−$5.6MMar ’26−$15,000Jun ’26
Fiscal years, by the month each ended
LineJun 2022Jun 2023Jun 2024Jun 2025Jun 2026
Revenue$96.7M$107.4M$65.2M$66.4M$57.6M
Gross profit$52.3M$66.6M$49.1M$45.8M$36.8M
Operating income−$109.9M−$17.1M−$1.6M−$7.8M−$8.3M
Net income−$108.8M−$17.1M−$15.8M−$13.6M−$14.3M
Operating cash flow−$28.8M−$5.1M−$1.4M−$1.9M$3.3M
Free cash flow−$28.8Mnone on file−$1.7M−$2.2M$3.3M
Cash$19.4M$23.0M$20.0M$31.0M$26.3M
Debt$14.4M$14.8M$12.7M$12.8M$11.0M
Shares outstanding1.9M5.5M6.0M9.0M10.7M